trump blueprint lower drug price offer minor chang
pharma biotech moat impact
page full analyst note may
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research may
estim apr
price data jun
rate updat jun
currenc amount express
valuat growth profit
methodolog valu compani
root provid supportive-car product kidney
diseas cancer patient free cash flow percentag
sale hover near firm undertak massiv
cost-cut
blockbust like prolia/xgeva futur blockbust cholesterol
drug repatha defend wide moat eros due
biosimilar brand competit
biolog vulner biosimilar
age eas manufactur innov brand drug
also steal share tougher label reimburs
affect anemia drug epogen aranesp sinc safeti concern
emerg neutropenia blockbust
neulasta direct biosimilar competit europ unit
state teva launch granix brand version
sandoz novarti launch biosimilar version
zarxio biosimilar version epogen neulasta
also approach market launch expect earli
biosimilar neulasta biosimilar epogen
final brand competitor pois continu erod
enbrel share think at-risk launch could result
biosimilar humira weigh enbrel sale
address headwind invest heavili
effici manufactur undertaken massiv cost-cut
program pois improv margin larg
biosimilar pipelin low manufactur cost could make
viabl competitor nascent market well
newest drug pipelin also key
counter challeng prolia osteoporosi xgeva
fractur prevent cancer patient approv
see billion peak sale kyproli -- acquir
onyx pois becom billion product multipl
myeloma repatha cholesterol-low look like biggest
opportun estim billion peak sale
also bullish posit aimovig launch
migrain tezepelumab phase asthma
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
leader biotechnology-bas human therapeut
histor expertis renal diseas cancer support care product
flagship drug includ red blood cell booster epogen aranesp immun
system booster neulasta enbrel inflammatori
diseas introduc first cancer therapeut vectibix
receiv approv bone-strengthen drug prolia/xgeva
acquisit onyx bolster firm therapeut oncolog
portfolio nexavar kyproli
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
trump blueprint lower drug price offer minor
chang pharma biotech moat impact
administr blueprint lower drug price reduc
out-of-pocket cost offer propos dont impact
moat rate pharma industri
price power brand drug still look
transpar provid inform help
patient lower out-of-pocket cost believ
limit impact brand drug price mild
polici propos appear larg build
budget propos drug white paper issu
council econom advisor februari aggreg
think propos would like impact less
drug spend exclud potenti chang
negoti medicar part drug could offer
anoth reduct drug spend depend
exact implement
overal blueprint propos creat minor headwind
brand drug price regard propos increas
gener competit view brand drug
industri tactic
limit gener competit
rel ineffect gener biolog biosimilar
larg assum swift competit follow patent
loss alreadi line polici effort
increas gener competit hard-to-mak drug
polici propos limit use risk evalu
mitig strategi delay gener competit rare
use could potenti impact drug firm
exampl celgen key drug revlimid could face
addit gener rapid launch gener
review fda
propos increas negoti around part drug
look like substant propos drug
histor face much price pressur note
drug tend least interchang
competit make negoti drug price
difficult polici propos regard incent
lower drug list price price transpar
direct-to-consum ad inform view
limit potenti reduc price lastli
focu lower out-of-pocket drug cost allow
cost-sav inform pharmacist provid
inform lower-cost altern treatment option
medicar patient could provid minor cost save
would significantli alter price power brand
within polici propos beyond immedi
action outlin administr provid
opportun explor addit cost save
granular propos limit view
major addit opportun focus
close rel smaller price loophol explor
altern price model value-bas
reimburs new strategi around medicaid drug
price believ innov brand drug
abl thrive environ major current
brand drug develop alreadi focus
innov meet increas demand privat sector
payer pharmaci benefit manag pbm
addit two opportun explor could
significantli help brand drugmak first propos
limit abil pbm reli rebat drug firm
lower drug cost could forc transpar
upfront price discount potenti give drug firm
power set price second effort make
countri pay drug hold potenti increas
global price power view initi larg
polit driven difficult implement
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
continu declin brand aranesp competit
mircera well epogen biosimilar launch expect
weigh anemia drug sale expect
neulasta sale begin fall significantli
biosimilar could enter market assum
averag annual declin neutropenia franchis
neulasta next year
expect combin prolia/xgeva sale peak
billion also forecast peak cholesterol-low sale
billion includ repatha sale well assum
royalti praluent sale begin
assign probabl approv even
osteoporosi aimovig migrain assum peak
sale billion also see newer cancer
drug like blincyto imlyg smaller opportun
billion peak follow posit data
endeavor studi think sale onyx
kyproli could peak billion
assum cost capit still rate
systemat risk surround share
averag cost equiti assumpt align
capit cost assumpt return equiti investor
like demand long run
access previous off-shore cash expect firm
emphas dividend share repurchas
model slightli declin gross debt level near term
note debt level could easili increas amgen
pre-tax cost debt reflect normal long-term
confid capabl defend
bottom-lin key period weak legaci
product cost-cut manufactur innov help
trim oper cost howev abil grow
heavili depend repatha abil move past payer
background polici propos
enact pleas see healthcar observ drug
price reform weigh valuat moat look
secur biotech industri look under-valued
valuat growth profit feb
rais fair valu estim per share
tax rate lower
expect follow tax reform think firm
capabl averag top-lin sale growth
bottom-lin growth enbrel profit share
end signific cost-cut non-gaap
oper margin improv nearli
expect margin remain
even addit invest sg due
improv also give us increas confid
potenti biosimilar pipelin compet
global includ billion biosimilar sale
price power erod at-risk humira
biosimilar launch possibl think enbrel sale
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
restrict well futur potenti restrict
aimovig migrain even osteoporosi
therefor assign diversifi biotech medium
repatha sale assumpt well futur oper
margin key assumpt behind fair valu
estim base-cas scenario assum adjust
oper margin declin remain
 sale praluent revenu
repatha praluent reach almost billion
bull-cas scenario assum improv adjust
oper margin reach nearli
assum obtain royalti sale
praluent revenu hit billion
result fair valu estim per
bear-cas scenario assum adjust oper
margin declin repatha
sale billion assum praluent royalti
persist difficulti payer reimburs result
fair valu estim per share
market sever blockbust biolog therapi
oncolog immunolog market give
intang asset form foundat wide moat
one origin biotech launch innov
anemia neutropenia
begin epogen
longer-act product aranesp neulasta
launch firm decid acquir
immunex bring enbrel portfolio highli
profit biolog continu drive strong free cash
flow firm gener around sale expect
see steadi free cash flow margin level
return invest capit remain cost
capit forese futur
continu grow despit steadi regulatori
epogen aranesp sinc well establish
biosimilar competit anemia neutropenia drug
europ gener biosimilar pressur sever
biolog tradit pharmaceut larg
manufactur difficulti cost clinic
trial product market creat high barrier
entri limit number entrant addit
longer-act product aranesp neulasta
help defend biosimilar threat older product
also highli diversifi enbrel account
sale repatha pois top
product sale strong growth enbrel
neutropenia drug counter epogen aranesp
headwind past year prolia/xgeva
approv osteoporosi cancer indic
reach blockbust statu renal diseas
drug sensipar onyx acquisit multipl
myeloma drug kyproli gener strong data
expand sale support european launch
think drug could becom lead proteasom
inhibitor billion rapidli grow market
see moat trend stabl think newli
launch product higher rate product
late-stag pipelin -- brand biosimilar -- allow
firm sustain strong roic new lower-cost
manufactur technolog aggress cost-cut
effort price volum pressur biosimilar
competit weigh heavili long-term margin
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
repatha launch europ expect
antibodi class could gener billion
peak sale sanofi/regeneron praluent
remain well ahead key competitor inclisiran medicin
superior endpoint forteo phase trial
cardiovascular side effect could limit broad
uptak drug bone-form mechan action
could launch see billion peak potenti
also bullish abil compet
biosimilar market given firm effici manufactur
practic establish oncolog immunolog salesforc
regulatori legal expertis advanc pipelin
assum partner allergan hold
share global biosimilar market
believ manufactur improv could boost
biosimilar emerging-market opportun
reimburs new competit brand
biosimilar biggest headwind moat
trend reimburs dialysi drug epogen bundl
dialysi product although contract
competit price margin pressur
product also among oldest --
profit -- market biolog mani among
first see biosimilar competit key patent
epogen neulasta expir
three product account top line
biosimilar version product
market europ howev declin rel
light far amgen epogen sale focus
 brand neulasta shield biosimilar
 teva brand
neutropenia product granix launch sandoz
biosimilar version zarxio approv
launch sandoz neulasta biosimilar
epogen biosimilar receiv complet respons
letter fda expect biosimilar
competit neulasta epogen
overal expect averag annual sale declin
epogen neutropenia franchis
addit arthriti psoriasi drug enbrel see
high level new competit assum double-digit
sale declin humira biosimilar launch
howev regard pipelin product think amgen
turn corner think firm begin see
low-single-digit top-lin growth despit pressur
current blockbust histor high
failur rate pipelin particularli oncolog pipelin
decis return
brodalumab right astra due higher rate suicid
also hit late-stag pipelin howev
amgen promis new drug cholesterol drug
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
pipelin product sinc
launch prolia/xgeva cholesterol drug repatha
upcom launch migrain reviv
enthusiasm firm research engin
acquisit decod give firm
abil identifi potenti new drug target valid
human genet
improv manufactur effici
benefit gross margin also could give firm
cost advantag nascent biosimilar market
plan launch five product
obiosimilar market europ sinc
teva brand granix well sandoz
biosimilar zarxio compet
 market biosimilar could larger impact
 neulasta
oth payoff billion acquisit
onyx highli depend success kyproli
johnson johnson/genmab darzalex like
strong competit
lack focu biotech peer
drug target larg market like osteoporosi
cardiolog specialti market like immunolog
oncolog
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
end held billion cash
billion debt expect gener roughli
billion free cash flow annual next year
combin one-tim repatri off-shore cash
end suffici handl
debt come due well firm share-repurchas
program billion author repurchas end
dividend program dividend rise
surpass billion
regulatori reimburs chang could continu
plagu aranesp epogen includ medicar dialysi
reimburs cut biosimilar competit two
key franchis alreadi exist europ
fda begin approv biosimilar unit state
teva brand product granix compet
neutropenia drug unit state
sandoz biosimilar enbrel key growth driver
grow competit rheumatoid
arthriti psoriasi could weigh firm
market share price power evapor
overal price power could wane propos reduct
medicar part reimburs implement given
firm relianc medicar high proport
sale addit sever newer product
enter highli competit market prolia compet
establish drug novarti reclast cheaper
gener bisphosphon vectibix compet roch
avastin bristol-my squibb erbitux
first head-to-head studi kyproli lead
proteasom inhibitor velcad posit
comparison fail differenti kyproli first-lin
set billion acquisit onyx could
prove expens repatha shown signific abil
reduc advers cardiovascular event benefit may
enough loosen payer restrict limit patient
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
access drug
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
repres date owner name posit common share held report holder issuer
va collegeamerica invmt co america
govern pension fund norway global
amgen retir save
new york mellon corp
fidel manag research compani
share
fund
share
fund
assign amgen standard mark stewardship
firm research develop engin
struggl churn promis drug candid sinc
launch prolia/xgeva believ new blood might
benefici firm product futur share
perform sale profit skyrocket
reign ceo chairman kevin sharer
signific multipl compress led flat perform
firm share tenur former presid
bob bradway replac sharer ceo may
board chairman start bradway
advanc sinc arriv vice presid
oper wish firm select
someon longer record pharmaceut industri
bradway morgan stanley
year think experi would particularli use
firm face steep biosimilar competit
need cohes strategi hope keep top-lin
growth posit territori said cfo david melin
appear make necessari cost cut
perlmutt head research develop retir
februari replac sean harper harper
sinc think medic background
experi senior vice presid global
develop serv well
make sever shareholder-friendli
move recent histori share repurchas tender
offer level fair valu estim appear
good use cash quarterli dividend grew roughli
annual initi level howev
remain wari firm compens polici
reward execut easili manipul earn per
share growth instead return invest capit
board structur enough healthcare-rel experi
board member former ceo robert
eckert media execut frank biondi jr
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
trump drug look modestli lower drug price
keep pharma biotech moat intact may
trump polici speech lower drug price didnt offer
mani specif focus mostli reduc middleman
profit rais drug price oversea base
 govern budget propos council
econom advisor white paper drug polici expect
modest neg headwind brand drug price
continu view moat within pharma/biotech
industri intact support strong price power
patent protect drug view brand drug group
aggreg under-valued expect group digest
modest price headwind major impact
valuat view roch sanofi allergan
under-valued wide moat drug firm
biggest neg seen administr
propos shift medicar part drug part
scenario price decreas drug
pharma earn would like fall close
heavier hit firm exposur
drug channel regeneron beyond
polici modestli neg polici propos includ
test new price program medicaid modifi
exclus rule increas gener competit
increas medicar part negoti power
modifi payment structur medicar part
exclud shift part medicar
estim save initi look like less
 drug spend
like give drug compani power drug price
howev either polici implement
would expect major windfal brand drug industri
background polici propos
enact pleas see healthcar observ drug
price reform weigh valuat moat look
secur biotech industri look under-valued within
report highlight impact enact chang
drug payment increas discount
medicar part doughnut hole sale also review
depth drug polici propos council
econom advisor budget
under-valued first quarter repatha
aimovig counter neulasta threat apr
maintain per share fair valu estim
wide moat rate follow steadi first-
quarter result reflect double-digit growth
newer franchis continu pressur three
largest franchis immunolog drug enbrel
support care drug neulasta aranesp
respect weve slightli lower sale
forecast kyproli aranesp enbrel repatha
lower assum tax rate increas assumpt
sever drug prolia vectibix nplate
biosimilar amjevita balanc impact valuat
overal expect continu struggl see
signific top-lin growth given signific biosimilar
brand pressur investor well awar
challeng firm plenti cash billion
end quarter support acquisit bolster
posit polici propos brand drug
offer well implement seem unlik
notabl demand countri pay drug
seem difficult implement also break
pharmaci benefit manag increas competit would
juggl sever differ type uncertainti
gener biosimilar competit drug
reimburs negoti busi develop
strategi headwind includ time neulasta
competit anticip second half
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
 sensipar gener competit assum
long run howev
interest mix drug candid less tradit area
focu cardiolog bone health well oncolog one
drug develop test bispecif
car-t cell therapi approach program
continu pass clinic studi need
support continu growth prolia well strong
sale ramp cholesterol-low drug repatha
new cardiovascular outcom label
migrain drug aimovig pois launch follow fda
approv may
coronari heart diseas unstabl angina requir
hospit similar benefit seen
amgen repatha differ outcom studi slightli
less sick patient strong p-valu studi
also show praluent caus reduct all-caus
death patient popul cholesterol
mg/dl reduct all-caus death
impress importantli signific safeti signal
seen across studi almost patient
american colleg cardiolog meet data
present doctor survey state
would chang prescrib habit data
first-quart product sale growth filter
increas non-gaap oper incom
oper margin fell basi point first
quarter due invest on-going upcom
repurchas boost earn per share time
growth difficult come support
non-gaap ep growth quarter
sanofi regeneron report strong praluent data
sanofi regeneron announc posit outcom data
partner cardiovascular drug praluent support
drug
under-valued stock call sanofi slightli under-valued
stock call regeneron expect posit data
dont expect major chang fair valu
estim compani solid data
reinforc compani moat strengthen
valu key drug portfolio
significantli reduc risk mace primari endpoint
base composit heart attack ischem stroke death
arm strong studi data sanofi regeneron
work drug price analysi group icer develop
plan address highli restrict formulari access
praluent face sinc approv
compani appear will leverag recent issu
icer report chang net price praluent close
recommend annual price rang
patient mg/dl
level exact price
depend risk factor price much
lower list price believ
signific rebat alreadi offer icer
estim peopl
acut coronari event level mg/
dl patient would ideal patient
praluent number support global estim
eur billion eur billion well ahead
consensu expect eur billion think peak
sale could eventu reach eur billion
litig front seek remov
praluent market due patent infring
believ remov market look like remot risk
point especi strong potenti
differenti mortal benefit praluent sanofi
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
program step firm tax rate allow
adjust ep growth disappoint firm
fundament busi pois growth non-
oper incom look flat pois
see acceler demand cholesterol drug repatha
billion peak sale potenti follow addit
drug cardiovascular benefit prescrib label
also pois launch migrain drug aimovig
demand osteoporosi drug prolia continu impress
wouldnt surpris see focu
acquisit fit franchis
pipelin beyond aimovig encourag
tezepelumab gener strong phase data
asthma current phase trial continu
point immuno oncolog program almost
program phase develop still preclin
skeptic firm abil catch
competitor like celgen bcma field especi given
celgen divers bcma pipelin detail
portfolio pipelin prospect pleas see
gener threat secur pharma
regeneron could hook damag on-going
royalti assum royalti
base-cas scenario district court rule
praluent infring two patent appeal
court deni request perman injunct
praluent remov market request
new trial believ lead eventu
settlement typic drug case like
complet review sanofi regeneron current
portfolio pipelin pleas see healthcar observ
pharma moat
rais fve improv tax outlook
slightli rais fair valu estim
per share follow result larg
due lower expect tax rate follow tax
reform amgen late-stag pipelin look rel thin
sever in-lin product still gener strong cash
flow almost billion off-shore cash
repatri free share buyback
dividend acquisit think mani
option boost long-term top-lin growth prospect
think wide moat rate stabl addit
firm manufactur effici could allow improv
gross margin feed save addit develop
promot effort
top line declin almost lower
oper cost partli boost end enbrel royalti
share repurchas push adjust ep
growth appear pois similar
top-lin declin pressur enbrel
anemia drug epogen aranesp continu sensipar
neulasta could face new gener biosimilar
threat massiv share billion repurchas
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
